Advancing Immuno-Oncology: The CytomX Story

PharmExec

5 Biotech Stocks a Pro Is Buying

Barron’s

Medidata Expands Partnership with CytomX Therapeutics to Centralize Management of Regulated and Nonregulated Content

BusinessWire

CytomX Announces Third Quarter 2017 Financial Results and Operational Progress

MarketWired

CytomX Therapeutics Appoints Charles S. Fuchs, M.D., MPH to Board of Directors

Globe Newswire

Applied BioMath, LLC and CytomX Therapeutics, Inc. Announce a Continuation of their Collaboration for Quantitative Systems Pharmacology Modeling in lmmuno-Oncology

CIsion PR Newswire

Amgen and CytomX Therapeutics Announce Partnership for Immuno-Oncology Research

Immuno-Oncology News

Biotech Giant Amgen Bets $1.5 Billion on Bay Area CytomX’s Cancer Drugs

Pharma Live

Amgen allies with CytomX Therapeutics on immuno-oncology

Zenopa

Amgen and CytomX Therapeutics Announce Strategic Collaboration in Immuno-Oncology

Drug Discovery & Development

Amgen announces new T-cell collaboration

Pharma Times

Amgen to Collaborate With CytomX on Cancer Treatment

San Fernando Valley Business journal

Amgen pledges $1.5bn for CytomX preclinical cancer drugs

PM Live

CytomX stock rockets 35% after deal with Amgen

MarketWatch

What CytomX Gets From Its Huge Amgen Collaboration

24/7 WallStreet

Amgen Enters Into an Immuno-Oncology Partnership With CytomX

Zacks

CytomX Breaks Out On Mash-Up With Amgen In Immuno-Oncology

Investor’s Business Daily

Taking a Fresh Look at CytomX Therapeutics, Inc. (CTMX)

Stock News journal

Amgen, CytomX Join in Immuno-Oncology Collaboration

NASDAQ

CytomX Therapeutics Holding On To Strong Gain In Late-Day Trading

Markets Insider

CytomX Announces Upcoming Trials in Progress Poster Presentations at European Society for Medical Oncology Annual Meeting

Globe Newswire

CytomX (CTMX) Announces Second Quarter 2017 Financial Results and Mid-Year Update Webcast Conference Call

BioSpace

Testing underway for CytomX’s immunotherapy drug for cancer patients

Patient Daily

CytomX Announces Upcoming Poster Presentation at American Society for Clinical Oncology Annual Meeting

Globe Newswire

CytomX Announces Management Team Changes

Globe Newswire

CytomX Therapeutics Appoints Marion McCourt to Board of Directors

Globe Newswire

Bristol-Myers Squibb’s Motivation Behind CytomX Deal

NASDAQ

Bristol-Meyer, CytomX extend work against cancer

Salt Lake Tribune

Bristol-Myers Squibb and CytomX Therapeutics Extend Worldwide Collaboration to Discover Probody™ Therapeutics for the Treatment of Cancer and Other Diseases

Bristol Myers Squibb

CytomX Therapeutics Announces Teleconference and Webcast to Provide Corporate Update

globe Newswire

CytomX Announces Full-Year 2016 Financial Results

Globe Newswire

CytomX Therapeutics to Present at Upcoming Investor Conferences

SAT Press Releases

CytomX Announces the First Patient Treated in Phase 1/2 PROCLAIM-072 Trial

Sat Press Releases

CytomX Announces the First Patient Treated in Phase 1/2 PROCLAIM-072 Trial

Yahoo! Finance

Brief-Applied Biomath Says To Collaborate With CytomX Therapeutics

Reuters

Applied BioMath, LLC and CytomX Therapeutics, Inc. announce a collaboration to develop a Quantitative Systems Pharmacology Probody platform model for use in lmmuno-Oncology

PRNewswire

CytomX Announces Fourth Target Selection by Bristol-Myers Squibb Under Strategic Oncology Collaboration

click here

CytomX to Present at the Jefferies 2016 London Healthcare Conference

click here

CytomX Therapeutics Announces Third Quarter 2016 Financial Results and Provides Pipeline Update

click here

CytomX Therapeutics Inc Pipeline Review – Analysis Of Key Players And Enlists All Their Major And Minor Projects 2016

click here

CytomX Therapeutics Appoints John A. Scarlett, M.D., to Board of Directors

click here

CytomX Therapeutics Inc (CTMX) Stock Rating Upgraded by Zacks Investment Research

click here

Top Wall Street Stories: CytomX Therapeutics, Inc. (NASDAQ:CTMX)

click here

Deal Spree for AbbVie Continues with $500 Million Cancer Tie-Up with CytomX

click here

CytomX and AbbVie Announce Strategic Collaboration for Probody Drug Conjugates

click here

CytomX (CTMX), AbbVie (ABBV) Enter Collaboration to Develop Probody Drug Conjugates Against CD71

click here

Tech Coast Angels Invested $13.5 Million into Startup Ecosystem in 2015

Southern California Angel Network Realizes Fourth Highest Investment Total in its 19-Year History

IRVINE, Calif. – February 29, 2016 – Tech Coast Angels (TCA) invested $13.5 million in a total of 58 companies in a diverse mix of industries in 2015. In addition to the $13.5 million of direct investment by TCA or its ACE Fund, the angel network also helped companies in its portfolio obtain $82 million through additional funding sources in 2015.

The angel network’s total direct investment for the year was slightly off its record $16.7 million year in 2014, consistent with the market slowdown in investments towards the end of 2015. The only other years in which TCA exceeded 2015’s total for investments were in 1999 ($16.3 million) and 2013 ($14.9 million).  Investment in new companies was 35% of the total last year, compared to 41% in 2014 and 63% in 2013.  Please see TCA’s 2015 year-end report for further details, a summarization of 2015, the outlook for 2016, and charts that segment TCA’s investments by industry.

“Notwithstanding the turmoil in financial markets in the latter part of the year, our numbers for 2015 reflect our confidence in adding value to innovative, early-stage companies—as well as expansion investments to our existing portfolio companies,” said TCA Chairman, John Harbison.  “Tech Coast Angels remains one of the largest and most influential angel networks because of our commitment to solid and collaborative relationships within the investment and entrepreneurial communities.”

The angel network also had six exits in 2015, including two successful IPOs (Mindbody, CytomX) and) and four acquisitions (CRISI Medical Systems, Olive Medical, Thermark and Wispry). This brings the total exits since the network’s inception in 1997 to 60.

“Early-stage investing is often a long-term commitment, and Tech Coast Angels members remain steadfast in providing support, both financially and experientially, to early-stage, high-growth companies—especially those in Southern California,” continued Mr. Harbison.  “We are looking forward to continuing our success in 2016 with our existing portfolio companies and by encouraging new young companies with great ideas.”

About Tech Coast Angels:

Tech Coast Angels (TCA) is one of the largest angel investment groups in the US.  The group comprises over 300 angel members with experience spanning all aspects of successful leadership in almost every industry in five networks that encompass Southern California.  TCA is the leader in providing funding, guidance, mentorship and leadership experience to early-stage, high-growth, exciting companies in Southern California.  CB Insights has ranked TCA ahead of all other angel groups as the strongest network in the country.

Since its founding in 1997, Tech Coast Angels have invested over $176 million in more than 300 companies and have helped attract more than $1.5 billion in additional capital/follow-on rounds, mostly from venture capital firms. For more information, please visit www.techcoastangels.com.